SEC INSIDER TRANSACTIONS

GILEAD SCIENCES, INC. (GILD) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

GILD · GILEAD SCIENCES, INC.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 34 filings · fetched 2026-11-13T18:00:06Z

Recent reported activity

0purchase rows on this page

7sale rows on this page

110matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-09-15Filed 2026-09-16	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	3,000D	145.29	Direct	Form 4 ↗0001310204-26-000029
2026-09-10Filed 2026-09-11	Cain Wettan Keeley MOfficer · EVP Gen Counsel, Legal & Comp Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	590D	—	Direct	Form 4 ↗0002110603-26-000013
2026-09-10Filed 2026-09-11	Cain Wettan Keeley MOfficer · EVP Gen Counsel, Legal & Comp Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	285D	144.81	Direct	Form 4 ↗0002110603-26-000013
2026-09-10Filed 2026-09-11	Cain Wettan Keeley MOfficer · EVP Gen Counsel, Legal & Comp Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	590A	—	Direct	Form 4 ↗0002110603-26-000013
2026-09-10Filed 2026-09-11	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	2,797D	—	Direct	Form 4 ↗0001782135-26-000031
2026-09-10Filed 2026-09-11	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	1,347D	144.81	Direct	Form 4 ↗0001782135-26-000031
2026-09-10Filed 2026-09-11	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	2,797A	—	Direct	Form 4 ↗0001782135-26-000031
2026-09-10Filed 2026-09-11	Berger DietmarOfficer · Chief Medical Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	533D	—	Direct	Form 4 ↗0001739515-26-000011
2026-09-10Filed 2026-09-11	Berger DietmarOfficer · Chief Medical Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	263D	144.81	Direct	Form 4 ↗0001739515-26-000011
2026-09-10Filed 2026-09-11	Berger DietmarOfficer · Chief Medical Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	533A	—	Direct	Form 4 ↗0001739515-26-000011
2026-09-10Filed 2026-09-11	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	8,780D	—	Direct	Form 4 ↗0001638643-26-000033
2026-09-10Filed 2026-09-11	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	4,230D	144.81	Direct	Form 4 ↗0001638643-26-000033
2026-09-10Filed 2026-09-11	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	8,780A	—	Direct	Form 4 ↗0001638643-26-000033
2026-09-10Filed 2026-09-11	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	2,797D	—	Direct	Form 4 ↗0001310204-26-000027
2026-09-10Filed 2026-09-11	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	1,347D	144.81	Direct	Form 4 ↗0001310204-26-000027
2026-09-10Filed 2026-09-11	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	2,797A	—	Direct	Form 4 ↗0001310204-26-000027
2026-09-01Filed 2026-09-02	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	5,408D	149.3817	Direct	Form 4 ↗0001638643-26-000031
2026-09-01Filed 2026-09-02	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	7,992D	148.3636	Direct	Form 4 ↗0001638643-26-000031
2026-09-01Filed 2026-09-02	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $146.94 to $147.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $147.95 to $148.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $148.96 to $149.94. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	1,600D	147.5087	Direct	Form 4 ↗0001638643-26-000031
2026-08-26Filed 2026-08-27	WELTERS ANTHONYDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F6 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. F7 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. References: F1, F7	M Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	10,282D	0	Direct	Form 4 ↗0001213307-26-000005
2026-08-26Filed 2026-08-27	WELTERS ANTHONYDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F6 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. F7 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. References: F1, F6	M Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	7,718D	0	Direct	Form 4 ↗0001213307-26-000005
2026-08-26Filed 2026-08-27	WELTERS ANTHONYDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F6 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. F7 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. References: F1, F5	S Sale (market/private)Common Stock · Non-derivative	6,880D	148.8227	Direct	Form 4 ↗0001213307-26-000005
2026-08-26Filed 2026-08-27	WELTERS ANTHONYDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F6 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. F7 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	3,402D	148.2353	Direct	Form 4 ↗0001213307-26-000005
2026-08-26Filed 2026-08-27	WELTERS ANTHONYDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F6 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. F7 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. References: F1	M Exercise / conversionCommon Stock · Non-derivative	10,282A	61.35	Direct	Form 4 ↗0001213307-26-000005
2026-08-26Filed 2026-08-27	WELTERS ANTHONYDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026. F2 Sale prices for the transactions reported range from $147.58 to $148.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $148.58 to $149.5799. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $147.57 to $148.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F5 Sale prices for the transactions reported range from $148.57 to $149.5699. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F6 100% of the shares subject to the stock option vested immediately upon the grant date of October 22, 2020. F7 25% of the shares subject to the option vested on each three-month anniversary measured from October 22, 2020 such that 100% of the shares subject to the option were fully vested and exercisable on October 22, 2021. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	4,600D	148.824	Direct	Form 4 ↗0001213307-26-000005

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.